Abbott vs. Johnson & Johnson: Divergent Paths of Split and Integration Reshape Medical Giants

A Look Back at the History of Healthcare: 15 Years Ago, Abbott and Johnson & Johnson (J&J) Were Both Giants Spanning Pharmaceuticals, Medical Devices, and Consumer Health. However, at That Time, Johnson & Johnson Was the Industry Leader, Outshining Abbott in Both Pharmaceuticals and Medical Devices. Its Market Value Was Nearly Three Times That of Abbott.

However, fifteen years later today, due to two different strategies adopted, it has led to Abbott (AbbVie) and Johnson & Johnson (Kenvue) undergo significant changes.

In 2011, Abbott announced a bold plan --- to split into two independent companies:

• Abbott(Keep the original name): Focus on medical devices and diagnostics business;

• AbbVie(New Company): Focus on innovative drug research and development.

The Logic Behind Abbott's Split

• Strategic Focus: The spin-off allows the two companies to free themselves from each other's business priorities and gain greater strategic and operational autonomy.

• Investor Preferences: The capital market prefers "pure play" enterprises. Pharmaceutical industry is a high-risk and high-return field, while the medical device industry is more stable. The spin-off allows investors to choose according to their risk preferences.

• Industry TrendsAt that time, giants such as General Electric (GE), Siemens, and Philips were all exploring the spin-off of non-core businesses to enhance agility.

In a nutshell: to create the maximum value for shareholders.

Split Results: Sixfold Growth in Six Years

After the spin-off was completed in 2013, AbbVie and Abbott were valued at $54 billion and $48 billion, respectively. Since then:

• Abbott Focuses on Medical Devices and Diagnostics, Becoming One of the Most Valuable Medtech Companies Globally;

• AbbVie Focuses on Innovative Drug R&D, Taking Higher Risks for Excess Returns.
  

Today, the combined market value of the two companies is nearly $600 billion, a six-fold increase since the spin-off, far surpassing Johnson & Johnson's growth of only two times during the same period.

Comparison: Johnson & Johnson's Conservative Strategy

Johnson & Johnson Chooses to Maintain Integration of Medical Technology and Pharmaceutical Businesses, Only Spinning Off the Smaller Consumer Health Unit (Kenvue) in 2023. This "Stability Strategy" Has Led to Its Growth Significantly Lagging Behind Abbott.

Enlightenment from Different Strategies of Abbott and Johnson & Johnson

Abbott's split is considered one of the most successful restructuring cases in the healthcare industry. Its success validates the effectiveness of a "focus strategy" within the complex healthcare ecosystem. Whether companies like Johnson & Johnson will follow similar strategies, unlocking shareholder value through spin-offs, is worth continued attention.